Shield Therapeutics plc (STX) - Total Liabilities
Based on the latest financial reports, Shield Therapeutics plc (STX) has total liabilities worth GBX76.96 Million GBX (≈ $9.36K USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Shield Therapeutics plc - Total Liabilities Trend (2013–2024)
This chart illustrates how Shield Therapeutics plc's total liabilities have evolved over time, based on quarterly financial data. See Shield Therapeutics plc current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Shield Therapeutics plc Competitors by Total Liabilities
The table below lists competitors of Shield Therapeutics plc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ovoca Gold PLC
IR:OVXA
|
Ireland | €967.00K |
|
Gateley (Holdings) Plc
LSE:GTLY
|
UK | GBX77.51 Million |
|
Maven Income And Growth Vct Plc
LSE:MIG1
|
UK | GBX449.00K |
|
Magnum Goldcorp Inc
V:MGI
|
Canada | CA$144.78K |
|
Profusa, Inc. Common Stock
NASDAQ:PFSA
|
USA | $29.06 Million |
|
Carr's Group plc
LSE:CARR
|
UK | GBX49.08 Million |
|
IMMUTABLE HOLDINGS INC.
F:B8X0
|
Germany | €185.77K |
Liability Composition Analysis (2013–2024)
This chart breaks down Shield Therapeutics plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see STX market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.83 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -5.18 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shield Therapeutics plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shield Therapeutics plc (2013–2024)
The table below shows the annual total liabilities of Shield Therapeutics plc from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | GBX46.95 Million ≈ $5.71K |
+77.25% |
| 2023-12-31 | GBX26.49 Million ≈ $3.22K |
+59.11% |
| 2022-12-31 | GBX16.65 Million ≈ $2.03K |
+392.51% |
| 2021-12-31 | GBX3.38 Million ≈ $411.25 |
+50.09% |
| 2020-12-31 | GBX2.25 Million ≈ $274.00 |
-46.05% |
| 2019-12-31 | GBX4.17 Million ≈ $507.86 |
+41.44% |
| 2018-12-31 | GBX2.95 Million ≈ $359.05 |
-21.58% |
| 2017-12-31 | GBX3.76 Million ≈ $457.85 |
-5.64% |
| 2016-12-31 | GBX3.99 Million ≈ $485.22 |
-81.45% |
| 2015-12-31 | GBX21.50 Million ≈ $2.62K |
+11.48% |
| 2014-12-31 | GBX19.29 Million ≈ $2.35K |
+139.66% |
| 2013-12-31 | GBX8.05 Million ≈ $979.21 |
-- |
About Shield Therapeutics plc
Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, the… Read more